Linked Life Data

20300982

Source:http://linkedlifedata.com/resource/pubmed/id/20300982

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20300982rdf:typepubmed:Citationlld:pubmed
pubmed-article:20300982lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0005961lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0237868lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C1167395lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0018133lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0679823lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0036679lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0439662lld:lifeskim
pubmed-article:20300982lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:20300982pubmed:issue3lld:pubmed
pubmed-article:20300982pubmed:dateCreated2010-4-5lld:pubmed
pubmed-article:20300982pubmed:abstractTextAllogeneic hematopoietic stem cell transplantation (HSCT) is associated with both graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects. In clinical studies of HLA-mismatched HSCT, strong GVL effects have been reported. In the present study, we addressed the mechanism of the GVL and GVH response using MHC-haploidentical murine bone marrow transplantation (BMT) models. Recipient BDF1 (H-2(b/d)) mice received T cell-depleted bone marrow and spleen cells from B6C3F1 (H-2(b/k)) or C57BL/6 (H-2(b)) mice with or without P815 mastocytoma cells (H-2(d)) after receiving lethal total body irradiation. B6C3F1 --> BDF1 (hetero-to-hetero type) recipients showed more powerful antileukemic effects with less severe GVHD than C57BL/6 --> BDF1 (parent-to-F1 type) recipients. Compared with C57BL/6 --> BDF1 recipients, significantly higher in vitro cytotoxic activity against P815 cells was observed in B6C3F1 --> BDF1 recipients. Significantly lower CXCR3 expression on donor T cells and higher interferon (IFN)-gamma expression were considered to be associated with strong antileukemic effects with less severe GVHD in B6C3F1 --> BDF1 recipients. Furthermore, host immune cells, especially natural killer cells and CD8(+) T cells, were found to contribute remarkably to high IFN-gamma production in B6C3F1 --> BDF1 recipients. Thus, in MHC-haploidentical HSCT, host immune cells may change the balance between GVH and GVL response through IFN-gamma production.lld:pubmed
pubmed-article:20300982pubmed:languageenglld:pubmed
pubmed-article:20300982pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20300982pubmed:citationSubsetIMlld:pubmed
pubmed-article:20300982pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20300982pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20300982pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20300982pubmed:statusMEDLINElld:pubmed
pubmed-article:20300982pubmed:monthAprlld:pubmed
pubmed-article:20300982pubmed:issn1865-3774lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:TamakiHiroyaHlld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:FujiokaTatsuy...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:OgawaHiroyasu...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:OkadaMasayaMlld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:OkamuraHaruki...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:IkegameKazuhi...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:TaniguchiYuki...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:YoshiharaSato...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:KuboShujiSlld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:SatakeAtsushi...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:ImadoTakehito...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:InoueTakayuki...lld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:XuYunfengYlld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:KaidaKatsujiKlld:pubmed
pubmed-article:20300982pubmed:authorpubmed-author:HoriuchiMarik...lld:pubmed
pubmed-article:20300982pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20300982pubmed:volume91lld:pubmed
pubmed-article:20300982pubmed:ownerNLMlld:pubmed
pubmed-article:20300982pubmed:authorsCompleteYlld:pubmed
pubmed-article:20300982pubmed:pagination485-97lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:meshHeadingpubmed-meshheading:20300982...lld:pubmed
pubmed-article:20300982pubmed:year2010lld:pubmed
pubmed-article:20300982pubmed:articleTitleSeparation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.lld:pubmed
pubmed-article:20300982pubmed:affiliationDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.lld:pubmed
pubmed-article:20300982pubmed:publicationTypeJournal Articlelld:pubmed